Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

A Survival Analysis of Pediatric Tonsillar Malignancies and Review of a Rare Case.

Janz TA, Nagasubramanian R, Wei JL.

Int J Pediatr Otorhinolaryngol. 2019 Mar;118:160-164. doi: 10.1016/j.ijporl.2018.12.033. Epub 2018 Dec 28.

PMID:
30639969
2.

Pediatric head and neck fibrosarcomas: A demographical, treatment, and survival analysis and review of a rare case.

Janz TA, Nagasubramanian R, Wei JL.

Int J Pediatr Otorhinolaryngol. 2019 Jan;116:92-96. doi: 10.1016/j.ijporl.2018.09.031. Epub 2018 Oct 2.

PMID:
30554717
3.

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.

DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS.

Cancer. 2018 Nov 1;124(21):4241-4247. doi: 10.1002/cncr.31701. Epub 2018 Sep 11.

4.

Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.

Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS.

Lancet Oncol. 2018 May;19(5):705-714. doi: 10.1016/S1470-2045(18)30119-0. Epub 2018 Mar 29. Erratum in: Lancet Oncol. 2018 May;19(5):e229.

5.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM.

N Engl J Med. 2018 Feb 22;378(8):731-739. doi: 10.1056/NEJMoa1714448.

6.

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.

Drilon A, Nagasubramanian R, Blake JF, Ku N, Tuch BB, Ebata K, Smith S, Lauriault V, Kolakowski GR, Brandhuber BJ, Larsen PD, Bouhana KS, Winski SL, Hamor R, Wu WI, Parker A, Morales TH, Sullivan FX, DeWolf WE, Wollenberg LA, Gordon PR, Douglas-Lindsay DN, Scaltriti M, Benayed R, Raj S, Hanusch B, Schram AM, Jonsson P, Berger MF, Hechtman JF, Taylor BS, Andrews S, Rothenberg SM, Hyman DM.

Cancer Discov. 2017 Sep;7(9):963-972. doi: 10.1158/2159-8290.CD-17-0507. Epub 2017 Jun 3.

7.

Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma.

Laetsch TW, Nagasubramanian R, Casanova M.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26593. Epub 2017 Apr 25. No abstract available.

PMID:
28440051
8.

Infantile Fibrosarcoma With NTRK3-ETV6 Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101.

Nagasubramanian R, Wei J, Gordon P, Rastatter JC, Cox MC, Pappo A.

Pediatr Blood Cancer. 2016 Aug;63(8):1468-70. doi: 10.1002/pbc.26026. Epub 2016 Apr 19.

9.

The current state of imaging pediatric hemoglobinopathies.

Dinan D, Epelman M, Guimaraes CV, Donnelly LF, Nagasubramanian R, Chauvin NA.

Semin Ultrasound CT MR. 2013 Dec;34(6):493-515. doi: 10.1053/j.sult.2013.05.005. Review.

PMID:
24332202
10.

Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.

Kwiatkowski JL, Cohen AR, Garro J, Alvarez O, Nagasubramanian R, Sarnaik S, Thompson A, Woods GM, Schultz W, Mortier N, Lane P, Mueller B, Yovetich N, Ware RE; SWiTCH Study Investigators.

Am J Hematol. 2012 Feb;87(2):221-3. doi: 10.1002/ajh.22228. Epub 2011 Nov 25.

11.

Genetic predictors for stroke in children with sickle cell anemia.

Flanagan JM, Frohlich DM, Howard TA, Schultz WH, Driscoll C, Nagasubramanian R, Mortier NA, Kimble AC, Aygun B, Adams RJ, Helms RW, Ware RE.

Blood. 2011 Jun 16;117(24):6681-4. doi: 10.1182/blood-2011-01-332205. Epub 2011 Apr 22.

12.

The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.

Innocenti F, Mirkov S, Nagasubramanian R, Ramírez J, Liu W, Bleibel WK, Shukla SJ, Hennessy K, Rosner GL, Cook E Jr, Eileen Dolan M, Ratain MJ.

Cancer Chemother Pharmacol. 2009 Apr;63(5):881-7. doi: 10.1007/s00280-008-0793-8. Epub 2008 Aug 2.

13.

Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure.

Nagasubramanian R, Hansen RJ, Delaney SM, Cherian MM, Samson LD, Kogan SC, Dolan ME.

Mutagenesis. 2008 Sep;23(5):341-6. doi: 10.1093/mutage/gen018. Epub 2008 May 13.

14.

Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice.

Hansen RJ, Nagasubramanian R, Delaney SM, Samson LD, Dolan ME.

Carcinogenesis. 2007 May;28(5):1111-6. Epub 2006 Nov 20.

PMID:
17116724
15.

Role of O6-alkylguanine-DNA alkyltransferase in protecting against 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced long-term toxicities.

Hansen RJ, Nagasubramanian R, Delaney SM, Cherian MM, Lin S, Kogan SC, Dolan ME.

J Pharmacol Exp Ther. 2005 Dec;315(3):1247-55. Epub 2005 Aug 26.

PMID:
16126841
16.

Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.

Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, Cook EH Jr, Badner JA.

Cancer Res. 2004 Jun 15;64(12):4353-6.

17.

Temozolomide: realizing the promise and potential.

Nagasubramanian R, Dolan ME.

Curr Opin Oncol. 2003 Nov;15(6):412-8. Review.

PMID:
14624222
18.

Pharmacogenetics in cancer treatment.

Nagasubramanian R, Innocenti F, Ratain MJ.

Annu Rev Med. 2003;54:437-52. Epub 2001 Dec 3. Review.

PMID:
12525681

Supplemental Content

Loading ...
Support Center